Pharmacological effects and therapeutic effects of Mirikizumab

Mirikizumab (Mirikizumab)-Omvoh is a humanized IgG4 monoclonal antibody specifically indicated for the treatment of patients with moderately to severely active ulcerative colitis. Its main mechanism of action is to selectively bind to the p19 subunit of human interleukin-23 (IL-23), thereby inhibiting the interaction between IL-23 and its receptor. IL-23 plays an important role in mucosal inflammation, affecting the differentiation, expansion, and survival of T cell subsets and innate immune cell subsets, which are the main sources of pro-inflammatory cytokines.

Research shows that militizumab can effectively improve intestinal inflammation and reduce the release of pro-inflammatory cytokines and chemokines by inhibiting the function of IL-23. Specifically, the mechanism of Milizumab involves the regulation of excessive production of pro-inflammatory cytokines, normalizing the pathogenesis of related inflammatory diseases such as ulcerative colitis. Through clinical experiments, it was found that in patients with ulcerative colitis treated in the induction and maintenance phases, there was a positive correlation between the average concentration of militizumab and the clinical remission rate and clinical response rate, which further proved its efficacy.

The clinical application of militizumab has brought new treatment options to patients with ulcerative colitis. By targetingIL-23's specific effect, it not only reduces symptoms, but may also improve patients' quality of life. With in-depth research on its pharmacological effects and therapeutic effects, militizumab is expected to play a greater role in future clinical practice and provide effective treatment options for more patients. In summary, militizumab has become an important drug in the treatment of moderate to severe ulcerative colitis due to its unique mechanism of action and good clinical effects.

Reference materials:https://go.drugbank.com/drugs/DB14910